Evolution of stents: past, present and future

References

• Moses JW, Leon MB, Popma J et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med.349, 1315–1323 (2003).
   PubMed Web of Science ®Google Scholar
• Schofer J, Schluter M, Gershlick AH et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet362, 1093–1099 (2003).
   PubMed Web of Science ®Google Scholar
• Schampaert E, Cohen EA, Schluter M et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J. Am. Coll. Cardiol.43, 1110–1115 (2004).
   PubMed Web of Science ®Google Scholar
• Daemen J, Ong AT, Stefanini GG et al. Three-year clinical follow-up of the unrestricted use of sirolimus-eluting stents as part of the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Am. J. Cardiol.98, 895–901 (2006).
   PubMed Web of Science ®Google Scholar
• Urban P, Gershlick AH, Guagliumi G et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cyphcr registry. Circulation113, 1434–1441 (2006).
   PubMed Web of Science ®Google Scholar
• Colombo A, Drzewiecki J, Banning A et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation108, 788–794 (2003).
   PubMed Web of Science ®Google Scholar
• Stone GW, Ellis SG, Cox DA et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med.350, 221–231 (2004).
   PubMed Web of Science ®Google Scholar
• Stone GW, Ellis SG, Cannon L et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare-metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA294, 1215–1223 (2005).
   PubMed Web of Science ®Google Scholar
• Meredith I, Ormiston J, Whitbourn R et al. First-in-human study of the endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I trial. EuroIntervention1, 157–164 (2005).
   PubMedGoogle Scholar
• Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med.346, 1773–1780 (2002).
   PubMed Web of Science ®Google Scholar
• Kandzari DE, Leon MB, Popma JJ et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J. Am. Coll. Cardiol.48, 2440–2447 (2006).
   PubMed Web of Science ®Google Scholar
• Chevalier B. A randomized, controlled trial to evaluate the safety and efficacy of the ZoMaxx Drug-Eluting Coronary Stent System compared to the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System in de novo coronary artery lesions. Presented at: Transcatheter Cardiovascular Therapeutics Symposium. Washington, DC, USA, 22–27 October 2006.
   Google Scholar
• Serruys P, Ong A, Piek JJ et al. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroIntervention1, 58–65 (2005).
   PubMedGoogle Scholar
• Serruys P, Ruygrok P, Neuzner J et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention2, 286–294 (2006).
   PubMedGoogle Scholar
• Stone GW, Midei M, Newman W et al; SPIRIT III Investigators. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation119, 680–686 (2009).
   PubMed Web of Science ®Google Scholar
• Grube E, Hauptmann K, Buellesfeld L, Lim V, Abizaid A. Six-month results of a randomized study to evaluate safety and efficacy of a biolimus A9 eluting stent with a biodegradable polymer coating. EuroIntervention1, 53–57 (2005).
   PubMedGoogle Scholar
• Chevalier B. NOBORI 1: part 1: a prospective, randomized trial of Biolimus A9 and paclitaxel-eluting stents: 9-month clinical and angiographic follow-up. Presented at: Transcatheter Cardiovascular Therapeutics Symposium. Washington, DC, USA, 22–27 October 2006.
   Google Scholar
• Morice MC, Wijns W, DiMario C et al. Direct stenting of de novo coronary stenoses with tacrolimus-eluting versus carbon-coated carbostents: the randomized JUPITER II trial. EuroIntervention2, 45–52 (2006).
   PubMedGoogle Scholar
• Romagnoli E, Leone AM, Burzotta F et al. Outcomes of the tacrolimus drug-eluting Janus stent: a prospective two-centre registry in high-risk patients. J. Cardiovasc. Med.9, 589–94 (2008).
   Google Scholar
• Tamburino C, Di Salvo ME, Capodanno D et al. Real world safety and efficacy of the Janus Tacrolimus-Eluting stent: long-term clinical outcome and angiographic findings from the Tacrolimus-Eluting Stent (TEST) registry. Catheter Cardiovasc. Interv.73, 243–248 (2009).
   PubMed Web of Science ®Google Scholar
• Ormiston J. ABSORB: first-in-man registry with the BVS bioabsorbable stent: thirty-day safety results. Presented at: Transcatheter Cardiovascular Therapeutics Symposium. Washington, DC, USA, 22–27 October 2006.
   Google Scholar
• Erbel R BJ, Koolen C. Coronary results of the first absorbable metal stent: the PROGRESS-I trial. Program and abstracts from the Innovation in Intervention Anual Scientific Sessions of the American College of Cardiology. Atlanta, GA, 13 March 2006.
   Google Scholar
• Tamburino C, La Manna A, Di Salvo ME et al. First-in-man one-year clinical outcomes of the CATANIA™ coronary stent system with NanoThin Polyzene®-F in de novo native coronary artery lesions: Assessment of The Latest Non-Thrombogenic Angioplasty Stent (ATLANTA) Trial. J. Am. Coll. Cardiol. Intv.2(3), 197–204 (2009)
   Google Scholar
• Mehilli J, Kastrati A, Wessely R et al. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation113, 273–279 (2006).
   PubMed Web of Science ®Google Scholar
• Serruys PW. The new Costar TM stent: twelve-month results with the new DES technology. Presented at: Congress of the EuroPCR. Paris, France, 24–25 May (2005).
   Google Scholar
• Aoki J, Serruys PW, van Beusekom H et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J. Am. Coll. Cardiol.45, 1574–1579 (2005).
   PubMed Web of Science ®Google Scholar
• Serruys P. The genous endothelial cell capture system final results from the HEALING II study. Presented at: Transcatheter Cardiovascular Therapeutics Symposium. Washington, DC, USA, 17–21 October 2005.
   Google Scholar
• Mehran R, Lansky A, Moses JW et al. AXXENT stent for the treatment of left main coronary artery bifurcation lesions. Am. J. Cardiol.98, TCT–113 (2006).
   Google Scholar
• Ako J, Bonneau HN, Honda Y, Fitzgerald PJ. Design criteria for the ideal drug-eluting stent. Am. J. Cardiol.100(Suppl.), 3M–9M (2007).
   PubMed Web of Science ®Google Scholar